Overview

Everything registered for Leap in 00-admin/artifacts.json, generated from the approved PreWiki projection

Overview

• 2026-08-28 - Phase 0 intake scaffolded.

2026-08-28 - Onboarding run 1 (Phases 0, 1, 1B)

Operator: John Ryan. Agent: oracle-client-onboarding.

• Scaffolded the 17-folder brain. Folder named Leap, not "LeapHealth", to honour the naming law.
• Swept the client shared drive Shared drives/LEAP/. Confirmed the two Drive IDs supplied by the
• Ruled out Shared drives/HealthLeap/ - a different client (Cedars-Sinai, nutrition/FNCE).
• Ingested: 36 logo files, 10 font files, the 33pp brand guidelines PDF, the client deck template,
• Crawled all 41 routes on leaphealth.com from its sitemap. Stack: Next.js + Prismic on Vercel.
• Captured 41 HTML pages, 38 CSS chunks (144 KB), the complete :root token set, 8 self-hosted font
• Populated overview, voice, proof points, ICP, offer, competitors, compliance, non-negotiables,
• Interview skipped: the Brand Foundation answers 11 of the 12 questions in the client's own words.

2026-08-28 - Phase 2, competitive analysis

Agent: oracle-competitive-analysis. Depth: standard.

• Registered and captured 8 supplied competitors, 1 adjacent incumbent from client canon (McKesson),
• Wrote 10 competitor profiles, a cross-competitor summary, positioning white space, and SEO/AEO
• Logged 7 claims requiring review and 4 new open questions.

Overview

Gated interview - ask one question at a time, record the answer verbatim, then pick the next highest-value gap. Skip any question the sources already answer. Stop when the first downstream use is unblocked; log the rest to open-questions.

Answers

Record answers below, tagged with date + speaker.

Overview

> Label every claim: source-backed (cite file) · operator-provided (person + date) · inferred (from what) · unknown. Metrics, outcomes, HIPAA/compliance, ROI = blocked until sourced.

Overview

> Label every claim: source-backed (cite file) · operator-provided (person + date) · inferred (from what) · unknown. Metrics, outcomes, HIPAA/compliance, ROI = blocked until sourced.

Overview

> Naming law, non-negotiable. The company is "Leap". Never "Leap Health" in any copy,

What Leap is

Leap is the healthcare company making specialty medicine more affordable and easier to access. It

• Category: specialty infusion benefit / drug distribution infrastructure
• Model: B2B2C. Sold to employers and their consultants; only works when an individual member
• Footprint: all 50 states, 200+ specialty therapies
• Stage: scaling. Began 2026 under 500K covered lives, targeting 3, 5M by year end (source-backed, Hani Elias via Brand Foundation)
• HQ: 1 Rockefeller Plaza, Second Floor, New York, NY 10020 (source-backed - Brand Guidelines p.26)

The mechanism, in one paragraph

Hospital outpatient departments and provider clinics buy infusion drugs at acquisition cost, mark

Positioning lines (verbatim, approved)

source-backed - Leap-Brand-Foundation, 2026-08-24.

Standard boilerplate (CEO-approved, Aug 2026 press release)

> Leap makes specialty medicine more affordable and easier to access. Available in all 50 states,

Leadership

source-backed - Leap-Brand-Foundation, 2026-08-24.

Overview

The short list. Break any of these and the work is wrong, not merely off-brand.

Naming

1. The company is Leap. Never "Leap Health" in copy. The only sanctioned appearance of the long

Copy

3. No em dashes. Spaced hyphens, commas or colons. (Sibei, 2026-08-24.)

Identity

13. The logo is never recoloured, rotated, skewed, distorted, re-typeset, rearranged or given

Claims

21. Any metric, ROI, clinical or outcome claim not on the approved list in

Related

voice-messaging · master-brand-guide · claims-compliance · proof-points

The two sources, and which one wins

Rule: the PDF owns the identity, the live site owns the interface, the Brand Foundation owns the

1. Logo

Assets: Brand Assets/Logos/ - EPS (CMYK / PMS / RGB / Black / White), SVG, PNG, JPG, plus a

• Clear space: the cap height of the letter L in "Leap", on all four sides. This is the
• Minimum size: print 0.25 in · digital 25 px · favicon 32 px
• Full colour on White, Ivory, or a very light photographic background. Also permitted on Rich
• One colour only where full colour is not feasible: black on white, white on black, white on

2. Colour

Full values, print codes and the print↔web reconciliation live in

3. Typography

Orbikular (CoType Foundry) is the primary face - a serif, used for display.

The alternate 'e'

Orbikular ships a stylistic set ss03 that swaps in an alternate lowercase e, and ss07 for

Print scale (PDF p.17: 22)

Colour may be used to bring attention to part of a headline where it breaks naturally (Navy +

Overview

Everything on this page is source-backed to Leap-Brand-Foundation, 2026-08-24 v2 (reconciled),

Voice in three words

Direct. Credible. Human.

Sibei's five rulings (2026-08-24) - these override the Editorial Style Guide

> The Editorial Style Guide itself is stale. The source document

Formatting essentials

• Sentence case everywhere, including headers, CTAs, and H1s
• Oxford (serial) comma required
• No em dashes. Spaced hyphens, commas, or colons instead
• Numbers: spell out one through nine, numerals for 10 and up
• Percent: use the % symbol
• Time: "7 a.m.", "9 p.m.", "7 a.m.-9 p.m."
• Dates: "January 7, 2026". No ordinals
• Medical conditions: lowercase - multiple sclerosis, lupus, Crohn's disease

Branded terms

• "Leap" - never "Leap Health"
• "Leap Care Guide" on first reference in member comms, then "Care Guide"
• Care Guide is title case

Hayden's grammatical style - long-form default, endorsed Aug 2026

• Cut throat-clearing preambles
• Everyday words over formal synonyms: "consequences", not "ramifications"
• "May" over "typically" / "would" / "must" for probabilistic claims
• "Such as:" to introduce example lists
• Contractions welcome
• Format times specifically: "8 a.m. to 5 p.m."
• No hedge closers
• Prefer bulleted lists over prose lists when items are parallel

Overview

> Label every claim: source-backed (cite file) · operator-provided (person + date) · inferred (from what) · unknown. Metrics, outcomes, HIPAA/compliance, ROI = blocked until sourced.

Overview

Leap is B2B2C. It sells to employers and their consultants, but the model only works when an

The named personas

Leap runs five HubSpot personas for the self-funded employer buying committee, plus two member

• The provider (prescribing physician and APP) - written clinician-to-clinician, citing INS, ONS
• The Care Guide team (internal) - written nurse-to-nurse.
• Talent - engineering, clinical and operations. Amir's directive is that talent and patients

1. Employer benefits and HR leaders - primary buyer

VP and Director of Benefits, Total Rewards and People Ops at self-insured employers, typically

2. CFOs and finance leaders

Care about payback period, claims-validated ROI, and the absence of hidden fees.

3. Benefits consultants and brokers - most important channel

Aon, Mercer, WTW, Alliant, Lockton, Gallagher, NFP, Hub, Brown & Brown.

4. Health plan and TPA partner managers

Influencers whose employer clients are asking what the plan is doing about infusion costs.

Overview

> Label every claim: source-backed (cite file) · operator-provided (person + date) · inferred (from what) · unknown. Metrics, outcomes, HIPAA/compliance, ROI = blocked until sourced.

The offer

A transparent specialty infusion benefit that sits inside the existing medical benefit as a

Packaging and pricing posture

No PMPMs. No fixed fees. No spread or markup on the drug. Billed only on care delivered.

The ten differentiators

1. Transparent specialty infusion benefit - every other US infusion company (Option Care, CVS Coram,

Go to market

Three motions: direct-to-jumbo, TPA channel, carrier and level-funded partnerships.

The Care Guide

Every member is paired with a dedicated Care Guide who coordinates the complete infusion journey.

Related

proof-points · audience-icp · market-competitors · claims-compliance

Overview

All figures source-backed to Leap-Brand-Foundation, 2026-08-24 v2, where they are listed under

Canonical Care Guide stat trio

Use these three together as a set: 98% patient satisfaction · 92 NPS · ~3 hours saved per

Worked pricing examples

source-backed - Leap-Brand-Foundation. Claim-risk medium: these are per-encounter examples,

The engagement continuum

> Utilization figures must be given as ranges. The Brand Foundation explicitly bans

Figures found on the brand guidelines PDF gradient page - DO NOT USE

Page 24 of the Leap Brand Guidelines (Jan 2026) shows three statistics inside the gradient device:

Attribution

Member quotes are always attributed generically - "Leap Member, 2026". Employer logos only where

Overview

> Label every claim: source-backed (cite file) · operator-provided (person + date) · inferred (from what) · unknown. Metrics, outcomes, HIPAA/compliance, ROI = blocked until sourced.

Overview

> Label every claim: source-backed (cite file) · operator-provided (person + date) · inferred (from what) · unknown. Metrics, outcomes, HIPAA/compliance, ROI = blocked until sourced.

Snapshot

Ten companies reviewed: eight supplied, one adjacent incumbent named in Leap's own canon, and one

Supplied Competitors

All eight supplied competitors were registered, captured and profiled. Two required non-standard

Discovered Competitors

Recommendation: add Navion to the monitored set as an AEO competitor. Do not add Galileo.

Category Battle

The category has converged on a shared problem statement. Lantern's infusion page cites a 300%

Messaging Patterns

"personalized", "convenient", "patient-focused", "specialized".

• Patient-first is the default. Eight of ten lead with patient experience. Category vocabulary is
• Bare numerals as proof. Paragon leads with five unlabelled statistics. Lantern leads with
• Nobody publishes a price. Not one of the ten publishes pricing logic, a fee structure, or a
• "Transparent" is being taken. Optum's "clear drug pricing" is the leading indicator.

Visual Brand Patterns

Assessed from 1440px homepage captures of all eleven companies, 2026-08-28.

• Palette is varied, not blue-dominant: Option Care leads with magenta, Paragon and Optum with
• Serif display is the modern signal. Three brands use it: Leap, Lantern and IVX. They are also
• Imagery is conventional across the board. Stock or commissioned photography of clinicians and
• Seven of eleven homepages were carrying a cookie or consent overlay at capture, several

Overview

Working notes from the competitive pass, 2026-08-28. Full profiles in competitor-profiles/,

The three findings that change how Leap should sell

1. Only two competitors speak to the employer. Nine of eleven address patients, referrers or

Capture notes

gets the block page unless a realistic user agent is set. Any future monitoring of this competitor

• IVX Health blocks scripted access. curl returns 403 behind Cloudflare, and headless Chrome
• Optum's infusion pages were not findable. Three obvious paths returned 404. The employer
• coramhc.com redirects to CVS Specialty. Coram's standalone infusion brand has effectively been

Discovered

genuine answer-engine rival: its infusion billing explainer surfaced ahead of Leap's own primary

• Navion (navionrx.com), pharmacy benefit navigation, formerly AlignRx. Not a deal rival but a
• Galileo (galileo.io) surfaced in the same search. Virtual-first care, not infusion-specific.

What was not done

Standard depth. Homepages for all, plus one solution page for Lantern and two pages for Navion.

Hard constraint on everything above

Leap canon forbids using a competitor's name as a foil, and the Author Persona lists it under what

Source Snapshot

• URL: https://www.coramhc.com/ (redirects to CVS Specialty)
• Date accessed: 2026-08-28
• Source type: competitor-owned homepage
• Raw source folder: 01-sources/raw-urls/2026-08-28/competitors/cvs-coram-home.html

Notable Finding

coramhc.com now resolves to CVS Specialty. Coram's standalone brand presence has effectively been

Messaging

• Homepage H1 (verbatim): "Helping you manage your therapy at your pace"
• Secondary H1 (verbatim): "CVS Specialty CareTeam"
• H2s (verbatim): "Easier refill", "Easier bill pay", "Manage your CVS Specialty medications"

Competitive Context

Care Guide, and it is backed by CVS scale. But it is positioned as therapy management for a patient

• Analyst read (inferred): the CareTeam construct is the closest competitive analogue to the Leap
• The vertical integration that makes CVS formidable also makes transparent pass-through pricing

Strengths

• Enormous scale and an existing member relationship through the pharmacy benefit.
• The CareTeam model is a real, resourced analogue to Leap's Care Guide.

Weaknesses Or Gaps

• No employer-facing infusion narrative surfaced (source-backed absence).
• Coram's distinct infusion identity has been diluted into a consumer pharmacy brand (source-backed).
• Cannot credibly sell "no spread, no markup" from inside a PBM (inferred).

Source Snapshot

below was read from the rendered DOM because the site blocks scripted fetches (source-backed).

• URL: https://www.ivxhealth.com/
• Date accessed: 2026-08-28
• Source type: competitor-owned homepage, read through a browser
• Raw source folder: 01-sources/raw-urls/2026-08-28/competitors/ivx-health-home.html contains a Cloudflare challenge page; the content

Messaging

"Private patient suites", "Convenient locations", "High-quality, personalized care",

• H1 (verbatim): "IVX Health Infusion Centers"
• H2s (verbatim): "Nationally recognized, locally known.", "Redefine your care experience",
• Meta (verbatim): "IVX Health outpatient infusion centers provide infusion and injection therapy

Competitive Context

IVX competes on experience, not economics. Private suites, TVs, flexible hours, a virtual tour.

• Analyst read (inferred): this is precisely the competitor Leap's site-of-care ceiling argument is

Strengths

• The best patient experience story in the captured set, by some distance.
• "In-Network Health Insurers" is a first-class nav item, signalling payer contracting maturity.
• Pediatric care as a named service line.

Weaknesses Or Gaps

• No employer narrative (source-backed absence).
• Cannot serve a member who needs or wants home infusion.
• Site-of-care economics only (inferred).

Client Implications

IVX is the competitor most likely to have already been bought by Leap's prospect. The sales motion is

Source Snapshot

• URL: https://www.kabafusion.com/
• Date accessed: 2026-08-28
• Source type: competitor-owned homepage
• Raw source folder: 01-sources/raw-urls/2026-08-28/competitors/kabafusion-home.html

Messaging

excels in its approach to patient care and positive clinical outcomes", "State-of-the-Art

• H2s (verbatim): "Patient-Focused Infusion Therapy", "KabaFusion is a home infusion company that

Competitive Context

(the midyear Gammagard member and the IVIG testimonial).

• Direct overlap with Leap on immunoglobulin, which is where two of Leap's own case studies land
• Analyst read (inferred): clinically credible, commercially conventional. Buy-and-bill.

Strengths

• Deep IVIG and pediatric capability (source-backed).
• Owns its own pharmacies, which is a real operational moat in specialty (source-backed).

Weaknesses Or Gaps

• No employer narrative (source-backed absence).
• No pricing transparency (source-backed absence).
• Recruitment messaging on the homepage suggests staffing constraints (inferred, weak signal).

Client Implications

On IVIG specifically, KabaFusion is a credible clinical alternative and Leap should not compete on

Source Snapshot

• URL: https://www.lanterncare.com/ and https://lanterncare.com/solutions-for-employers/infusions/
• Date accessed: 2026-08-28
• Source type: competitor-owned homepage and employer infusion solution page
• Raw source folder: 01-sources/raw-urls/2026-08-28/competitors/lantern-home.html, 01-sources/raw-urls/2026-08-28/competitors/lantern-infusions.html

Why This Profile Matters Most

Leap's own canon names Lantern as the company most commonly mentioned alongside Leap. This pass

Messaging

• H1 (verbatim): "Transform how your people get specialty care"
• H2 (verbatim): "12 million lives covered | $1 billion saved"
• H2 (verbatim): "Meet Lantern, the Specialty Care Platform"
• Infusions H1 (verbatim): "A better option for safe, convenient infusion therapy"
• Infusions H2s (verbatim): "Your Challenges", "The Lantern Infusion Care Difference"

Competitive Context

scale proof stated as lives and dollars (source-backed).

• Claimed differentiators: platform breadth across surgery and specialty, a curated network, and
• Analyst read (inferred): Lantern arrived at infusion from surgery, so its native construct is a
• Lantern's infusion page cites a 300% markup figure, close to Leap's "up to 400%" (source-backed).

Strengths

Leap's equivalent public proof is thinner.

• The only competitor speaking employer-first about infusion (source-backed).
• Hard, quantified scale proof on the homepage: 12 million lives, $1 billion saved (verbatim).
• Multi-category platform, so it can enter through surgery and expand into infusion.

Weaknesses Or Gaps

(inferred).

• Infusion is one solution inside a surgery-led platform, not the whole company (inferred).
• Steering is intrinsic to the model, which carries member-abrasion risk Leap explicitly avoids
• 30-40% is a narrower band than Leap's 30-60% (source-backed on both sides).

Overview

Seed list for the oracle-competitive-analysis pass. Every name below is source-backed to

Direct - infusion providers

All of these rely on buy-and-bill margin, which is the axis Leap competes on.

Partnership channels - NOT competitors

Carrum Health · Transcarent · HTA · BGH. Do not profile these as competition.

Policy and regulatory watchlist (Aug 2026)

• 340B drug discount program reform
• White bagging - control of drug sourcing
• Home infusion pushback, especially from oncology providers
• Prior authorization reform

Market context

Health spend growth ~9% in 2026, highest in 20 years. ~30 specialty drugs in 1995, nearly 1,000

Requested analysis

SEO/AEO opportunities

• Depth: standard
• Outputs: competitor profiles, CompIntel workbook, visual brand audit, positioning white space,
• Status: RUN 2026-08-28. Outputs: 10 competitor profiles, summary.md, positioning-white-space.md,

Source Snapshot

• URL: https://www.mckesson.com/
• Date accessed: 2026-08-28
• Source type: competitor-owned homepage
• Raw source folder: 01-sources/raw-urls/2026-08-28/competitors/mckesson-home.html

Why This Profile Exists

Leap's own positioning names McKesson: Leap is "modern drug distribution infrastructure", and the

Competitive Context

rival in a deal (inferred).

• McKesson does not compete with Leap for a benefits leader's budget. It is a category anchor, not a
• Analyst read (inferred): invoking McKesson is a category-creation move, not a competitive
• The risk is that "modern drug distribution infrastructure" means nothing to a VP of Benefits. It is

Client Implications

Keep the McKesson framing where it belongs: manufacturer conversations, partnership discussions,

Strategic Assessment

• Overall brand strength: 5/5.
• Messaging clarity: 3/5 as a corporate brand.
• Differentiation from Leap: 5/5. Different business entirely.
• Key threat to Leap: none directly. Distribution scale is a partner constraint, not a sales rival.
• Key opportunity for Leap: the category line is a good one, aimed at the right rooms only.

Source Snapshot

• URL: https://www.navionrx.com/
• Date accessed: 2026-08-28
• Source type: competitor-owned homepage plus a published article on infusion economics
• Raw source folder: 01-sources/raw-urls/2026-08-28/competitors/navion-home.html, 01-sources/raw-urls/2026-08-28/competitors/navion-infusion-costs.html

Discovery Note

Not in the supplied set. Surfaced during competitor expansion (source-backed, search

Why It Matters

Navion is competing for the same search and AI-answer real estate as Leap. Its article

Competitive Context

and its stated lever is site-of-care redirection. Same ceiling as IVX and Paragon.

• Analyst read (inferred): Navion frames infusion as one pharmacy-benefit problem among several,

Client Implications

Two actions. First, add Navion to the monitored set. Second, treat its content as the benchmark for

Strategic Assessment

• Overall brand strength: 2/5.
• Messaging clarity: 3/5.
• Differentiation from Leap: 4/5 on model, 2/5 on search visibility.
• Key threat to Leap: organic and AI-answer visibility on Leap's core query set.
• Key opportunity for Leap: outpublish it with primary evidence.

Source Snapshot

• URL: https://www.optioncarehealth.com/
• Date accessed: 2026-08-28
• Source type: competitor-owned homepage
• Raw source folder: 01-sources/raw-urls/2026-08-28/competitors/option-care-home.html

Brand Positioning

Positioning statement (inferred from homepage): the national-scale, clinically credible home infusion

Value Proposition

• Primary value prop: national reach plus clinical quality in home and alternate-site infusion.
• Proof points: not surfaced on the homepage (source-backed absence).

Messaging

strives to improve quality of care and reduce patient healthcare costs."

• Homepage H1 (verbatim): "Re-imagining infusion care"
• Homepage title (verbatim): "Infusion Therapy Services - Option Care Health"
• Meta description (verbatim): "The leading provider of home infusion services, Option Care Health

Competitive Context

drug spread has no commercial reason to publish acquisition cost, which is exactly the disclosure

• Claimed differentiator: scale and care quality (source-backed).
• Analyst read (inferred): revenue is earned on the drug. A provider whose margin sits inside the

Strengths

• Scale and national footprint (source-backed, self-claimed as leading provider).
• Clinical credibility with referrers, which is the channel that actually starts a therapy.
• Public-company resourcing and a mature payer contracting function (inferred).

Source Snapshot

here is the Optum Rx pharmacy benefit page, which is where the employer conversation actually lives.

• URL: https://www.optum.com/en/business/employers/pharmacy-care-services.html
• Date accessed: 2026-08-28
• Source type: competitor-owned employer page
• Raw source folder: 01-sources/raw-urls/2026-08-28/competitors/optum-infusion-home.html
• Note: the infusion-services URL paths tried first returned 404. The employer-facing page captured

Notable Finding

Optum is already using transparency language to employers: "clear drug pricing" (verbatim, meta

Messaging

advanced tech", "Guiding and designing your pharmacy benefit solutions", "Aligned to scale with

• H1 (verbatim): "Pharmacy benefit solutions built for you"
• H2s (verbatim): "How Optum Rx pharmacy benefits better serve you", "Smarter benefits with AI and

Competitive Context

"transparent" and far softer than "pass-through at acquisition cost", and it commits to nothing

• Claimed differentiator: scale, alignment, and clear pricing (source-backed).
• Analyst read (inferred): "clear" is doing a lot of work here. It is a softer word than

Strengths

• Owns the employer relationship already, through the pharmacy benefit.
• Can bundle infusion into an existing contract with no new vendor.
• Uses transparency language credibly enough to blunt a challenger's differentiation.

Weaknesses Or Gaps

(source-backed: three 404s before a working employer page was found).

• Infusion is buried. The infusion-specific pages were not discoverable at the obvious paths
• "Clear drug pricing" is unfalsifiable as stated (inferred).
• Structurally cannot pass through at acquisition cost without repricing its own economics (inferred).

Source Snapshot

• URL: https://www.paragoninfusion.com/
• Date accessed: 2026-08-28
• Source type: competitor-owned homepage
• Raw source folder: 01-sources/raw-urls/2026-08-28/competitors/paragon-home.html

Messaging

support designed to help patients access coordinated care."

• H1 (verbatim): "Paragon Infusion Centers and Specialty Pharmacies"
• H2 (verbatim): "Serving Patients and Physicians for 20 Years"
• Meta (verbatim): "Find Paragon infusion centers, specialty pharmacy services, and home infusion

Notable Pattern

Paragon leads with unlabelled scale numbers as its trust device: five H2 statistics with no unit

Competitive Context

acquisition cost is structurally weak, in the same way it is for Coram and Optum. Three of the

• Analyst read (inferred): payer ownership by Elevance means the incentive to surface true

Strengths

• Twenty-year operating history and physician relationships (source-backed).
• Multi-modal: centres, home, and specialty pharmacy.

Weaknesses Or Gaps

• No employer-facing narrative (source-backed absence).
• No pricing transparency (source-backed absence).
• Payer ownership constrains a transparent-pricing response (inferred).

The one-line finding

The category has agreed on the problem and split three ways on the mechanism. Leap owns the third

White space one: the artefact, not the adjective

Every competitor claims transparency in some form, and Optum now uses "clear drug pricing" from

White space two: the ceiling

Site-of-care programmes are the most common thing Leap's prospect has already bought. The buyer

White space three: the payer conflict, stated structurally

Three of seven direct competitors are payer or PBM owned. A fourth, Optum, is the PBM. None can

White space four: dual addressability

Competitors pick an audience. Leap is B2B2C by necessity: the employer buys it and the member has to

White space five: the visual system, which is not currently white space

This was checked against 1440px captures of all eleven homepages rather than assumed.

Source Snapshot

• URL: https://www.soleohealth.com/
• Date accessed: 2026-08-28
• Source type: competitor-owned homepage
• Raw source folder: 01-sources/raw-urls/2026-08-28/competitors/soleo-home.html

Messaging

Pharmacy™", "Featured Clinical Abstracts and Case Studies", "Patient Learning Center"

• H1 (verbatim): "Specialized Care for Every Patient, Every Condition"
• H2s (verbatim): "Simplifying Complex Care", "Patient Stories", "The Role of Our Complex Specialty

Notable Pattern

Soleo is the only captured competitor leading with clinical abstracts as a trust device. That is

Competitive Context

claims the hard cases, which insulates against a cheaper competitor by implying the cheap option

• Analyst read (inferred): "Complex Specialty Pharmacy" is a defensive category construction. It

Strengths

• Published clinical evidence (source-backed).
• A trademarked category construct, which is more brand discipline than most of the set shows.

Weaknesses Or Gaps

• No employer narrative (source-backed absence).
• No pricing transparency (source-backed absence).

Overview

> Label every claim: source-backed (cite file) · operator-provided (person + date) · inferred (from what) · unknown. Metrics, outcomes, HIPAA/compliance, ROI = blocked until sourced.

Motion

> The Leap Brand Guidelines publish no motion specification at all. Every value below is

Durations and distances

> Nothing on leaphealth.com bounces. The overshoot curve sits in :root and is referenced

The one motion idea worth naming

Every interactive element on the site moves forward and slightly up - the arrow nudges right,

Grounds

Three sanctioned dark grounds and two light. Full-colour logo works on all five.

• Light: White, Ivory #FAF3E9 - the preferred backgrounds
• Dark: Rich Navy #042A4F, Rich Emerald #004321, black (one-colour logo only)

Type behaviour

Orbikular for display and numerals; Saans for everything read in sentences. On the web Orbikular

The dash

The Leap dash is the brand's only owned graphic device. It means motion, connection, care and

Overview

> Label every claim: source-backed (cite file) · operator-provided (person + date) · inferred (from what) · unknown. Metrics, outcomes, HIPAA/compliance, ROI = blocked until sourced.

Why AEO matters more than usual for this account

Leap already holds the best AEO input document PreHealth has seen in a client account. The

The competitive picture

(source-backed, 41-route site capture 2026-08-28).

• Leap's /insights hub carries 24 articles across cost, clinical and partnership topics
• Navion, a pharmacy benefit navigator, surfaced ahead of Leap in a general search on infusion
• Lantern ranks for employer infusion queries with a dedicated /solutions-for-employers/infusions/
• No competitor in the set publishes a worked claim comparison, a J-code savings table, or a

Where Leap already wins

A search for transparent specialty infusion for self-insured employers returns Leap's own press

Opportunity one: the worked claim, as a page

Leap owns a before-and-after claim breakdown that nobody else in the category publishes. As a PDF

Opportunity two: the J-code savings table

The pricing overview holds a six-row table of J-codes, brand names, conditions, treatments per year,

Opportunity three: the site-of-care ceiling

Nobody has published the honest limit of site-of-care redirection. Leap has the figure.

Overview

> Label every claim: source-backed (cite file) · operator-provided (person + date) · inferred (from what) · unknown. Metrics, outcomes, HIPAA/compliance, ROI = blocked until sourced.

Overview

Leap operates inside employer medical benefits and speaks to patients about therapy. Claim

Blocked until sourced

Per PreHealth methodology, these are blocked unless the figure appears in proof-points or an

• any metric or percentage
• any healthcare or clinical outcome
• any HIPAA or compliance statement
• any ROI, payback or performance claim

Standing qualifiers

design."

• Member out-of-pocket claims must carry: "member responsibility is based on individual benefit
• Activation and utilization rates are given as ranges, never fixed numbers.
• Rob's ~2030 full-unbundling call is a prediction and must be labelled as one.

Attribution

in the client drive at 3) Client Supplied Assets/Proof Points/Video TestimonialsB2C Members/.

• Member quotes: "Leap Member, {year}", generic, always.
• Employer logos: only where contractual permission is confirmed.
• Patient testimonial video requires a signed release and HIPAA authorization - the template lives

Positioning guardrails

• Leap is not a carve-out and not a site-of-care redirector. Never frame it as either.
• Never imply Leap disrupts carriers, TPAs or PBMs.

Open compliance conflict

OQ-01 - "licensed Care Guide" in the CEO-approved boilerplate. The Aug 2026 press-release

Overview

> Label every claim: source-backed (cite file) · operator-provided (person + date) · inferred (from what) · unknown. Metrics, outcomes, HIPAA/compliance, ROI = blocked until sourced.

Overview

> Label every claim: source-backed (cite file) · operator-provided (person + date) · inferred (from what) · unknown. Metrics, outcomes, HIPAA/compliance, ROI = blocked until sourced.

Overview

> Label every claim: source-backed (cite file) · operator-provided (person + date) · inferred (from what) · unknown. Metrics, outcomes, HIPAA/compliance, ROI = blocked until sourced.

Overview

> Label every claim: source-backed (cite file) · operator-provided (person + date) · inferred (from what) · unknown. Metrics, outcomes, HIPAA/compliance, ROI = blocked until sourced.

Overview

Run status to auto-check these.

• [ ] 00-admin/source-register.md
• [ ] 02-foundation/client-overview.md
• [ ] 03-brand/voice-messaging.md
• [ ] 04-audience/audience-icp.md
• [ ] 05-offers-sales/offers-sales-context.md
• [ ] 07-market-competitors/market-competitors.md
• [ ] 10-oracle-instructions/claims-compliance.md
• [ ] 12-review-approvals/open-questions.md